Respiratory-system-drugs
PubMed Central: Published: July, 2021
Urticaria is a frequent, mast cell–driven disease that
presents with wheals, angioedema, or both. The lifetime prevalence for acute
urticaria is approximately 20%.
Chronic idiopathic urticaria (CIU) is a common skin condition
characterized by the appearance of recurrent wheals and/or angioede...
The rapidly escalating coronavirus
disease 2019 (COVID-19) pandemic has focused attention on the diagnosis and
treatment of patients with acute respiratory infection in an unprecedented
manner. Although most of the lung injury patients have is believed to be caused
by the virus, concern over bacterial co-infection also informs current
treatmen...
Antibiotics treatment for bacterial
pneumonia in adults in hospital
Antibiotic management of
suspected or confirmed bacterial pneumonia in adults in hospital during the
COVID-19 pandemic. This includes people presenting to hospital with moderate to
severe community-acquired pneumonia and people who develop pneumonia while in
hospital.COVID...
The COVID-19 pandemic has presented challenges in management and
follow-up in common respiratory diseases such as asthma.
This review will discuss the current recommendations regarding asthma and
COVID-19 based on best available evidence at this time. RemoveAvailable Brand
Montelukast is used to control
and prevent symptoms caused by asthma (such as wheezing and shortness of
breath). It is also used before exercise to prevent breathing problems during
exercise (bronchospasm).Montelukast is also used to
relieve symptoms of hay fever and allergic rhinitis (such as sneezing,
stuffy/runny/itchy nose).
Common Ast...
Montelukast is used to control and prevent symptoms caused by asthma. It is also used before exercise to prevent breathing problems during exercise (bronchospasm).Asthma Symptoms:Montelukast recommended dose is once a day in the evening and it’s important to take it regularly even when patient have no symptoms.Note: Montelukast is not a rescue medi...
Baricitinib plus remdesivir was superior to remdesivir alone in reducing
recovery time and accelerating improvement in clinical status among
patients with Covid-19, notably among those receiving high-flow oxygen
or noninvasive ventilation. The combination was associated with fewer
serious adverse events.
The U.S. Food and Drug
Administration issued an emergency use authorization (EUA) for the drug
baricitinib, in combination with remdesivir, for the treatment of suspected or
laboratory confirmed COVID-19 in hospitalized adults and pediatric patients two
years of age or older requiring supplemental oxygen, invasive mechanical...